Honors & Awards


  • CACA Student Excellence Award, Chinese American Chromatography Association (2024)
  • Gary B. and Janice L. Aspelin Excellence in Research Award, Department of Chemistry, University of Wisconsin-Madison (2024)
  • Wisconsin Human Proteomics Symposium Rising Star Award, Wisconsin Human Proteomics Symposium (2024)
  • Agilent Steve Berger Academic Award, Agilent Technologies Inc. (2023)
  • SRGC Travel Award, Graduate School, University of Wisconsin-Madison (2023)
  • Departmental Poster Session Poster Award, Department of Chemistry, University of Wisconsin-Madison (2022)
  • GSFLC Travel Award, Department of Chemistry, University of Wisconsin-Madison (2022)
  • Robert C. Doban Mentorship Award, Department of Chemistry, University of Wisconsin-Madison (2022)
  • Honored Instructor, University Housing, University of Wisconsin-Madison (2020)

Boards, Advisory Committees, Professional Organizations


  • Member, American Society for Mass Spectrometry (2019 - Present)

Professional Education


  • Ph.D., University of Wisconsin-Madison, Analytical Chemistry (2024)
  • B.S.(Honor), Wuhan University, Chemistry (2019)

Stanford Advisors


Lab Affiliations


All Publications


  • Spatially and temporally probing distinctive glycerophospholipid alterations in Alzheimer's disease mouse brain via high-resolution ion mobility-enabled sn-position resolved lipidomics. Nature communications Xu, S., Zhu, Z., Delafield, D. G., Rigby, M. J., Lu, G., Braun, M., Puglielli, L., Li, L. 2024; 15 (1): 6252

    Abstract

    Dysregulated glycerophospholipid (GP) metabolism in the brain is associated with the progression of neurodegenerative diseases including Alzheimer's disease (AD). Routine liquid chromatography-mass spectrometry (LC-MS)-based large-scale lipidomic methods often fail to elucidate subtle yet important structural features such as sn-position, hindering the precise interrogation of GP molecules. Leveraging high-resolution demultiplexing (HRdm) ion mobility spectrometry (IMS), we develop a four-dimensional (4D) lipidomic strategy to resolve GP sn-position isomers. We further construct a comprehensive experimental 4D GP database of 498 GPs identified from the mouse brain and an in-depth extended 4D library of 2500 GPs predicted by machine learning, enabling automated profiling of GPs with detailed acyl chain sn-position assignment. Analyzing three mouse brain regions (hippocampus, cerebellum, and cortex), we successfully identify a total of 592 GPs including 130 pairs of sn-position isomers. Further temporal GPs analysis in the three functional brain regions illustrates their metabolic alterations in AD progression.

    View details for DOI 10.1038/s41467-024-50299-9

    View details for PubMedID 39048572

    View details for PubMedCentralID PMC11269705

  • Lysine L-lactylation is the dominant lactylation isomer induced by glycolysis. Nature chemical biology Zhang, D., Gao, J., Zhu, Z., Mao, Q., Xu, Z., Singh, P. K., Rimayi, C. C., Moreno-Yruela, C., Xu, S., Li, G., Sin, Y. C., Chen, Y., Olsen, C. A., Snyder, N. W., Dai, L., Li, L., Zhao, Y. 2024

    Abstract

    Lysine L-lactylation (Kl-la) is a novel protein posttranslational modification (PTM) driven by L-lactate. This PTM has three isomers: Kl-la, N-ε-(carboxyethyl)-lysine (Kce) and D-lactyl-lysine (Kd-la), which are often confused in the context of the Warburg effect and nuclear presence. Here we introduce two methods to differentiate these isomers: a chemical derivatization and high-performance liquid chromatography analysis for efficient separation, and isomer-specific antibodies for high-selectivity identification. We demonstrated that Kl-la is the primary lactylation isomer on histones and dynamically regulated by glycolysis, not Kd-la or Kce, which are observed when the glyoxalase system was incomplete. The study also reveals that lactyl-coenzyme A, a precursor in L-lactylation, correlates positively with Kl-la levels. This work not only provides a methodology for distinguishing other PTM isomers, but also highlights Kl-la as the primary responder to glycolysis and the Warburg effect.

    View details for DOI 10.1038/s41589-024-01680-8

    View details for PubMedID 39030363

    View details for PubMedCentralID 8059378

  • CHRISTMAS: Chiral Pair Isobaric Labeling Strategy for Multiplexed Absolute Quantitation of Enantiomeric Amino Acids. Analytical chemistry Zhu, Z., Xu, S., Wang, Z., Delafield, D. G., Rigby, M. J., Lu, G., Gu, T. J., Liu, P. K., Ma, M., Puglielli, L., Li, L. 2023; 95 (50): 18504-18513

    Abstract

    Amino acids (AAs) in the d-form are involved in multiple pivotal neurological processes, although their l-enantiomers are most commonly found. Mass spectrometry-based analysis of low-abundance d-AAs has been hindered by challenging enantiomeric separation from l-AAs, low sensitivity for detection, and lack of suitable internal standards for accurate quantification. To address these critical gaps, N,N-dimethyl-l-leucine (l-DiLeu) tags are first validated as novel chiral derivatization reagents for chromatographic separation of 20 pairs of d/l-AAs, allowing the construction of a 4-plex isobaric labeling strategy for enantiomer-resolved quantification through single step tagging. Additionally, the creative design of N,N-dimethyl-d-leucine (d-DiLeu) reagents offers an alternative approach to generate analytically equivalent internal references of d-AAs using d-DiLeu-labeled l-AAs. By labeling cost-effective l-AA standards using paired d- and l-DiLeu, this approach not only enables absolute quantitation of both d-AAs and l-AAs from complex biological matrices with enhanced precision but also significantly boosts the combined signal intensities from all isobaric channels, greatly improving the detection and quantitation of low-abundance AAs, particularly d-AAs. We term this quantitative strategy CHRISTMAS, which stands for chiral pair isobaric labeling strategy for multiplexed absolute quantitation. Leveraging the ion mobility collision cross section (CCS) alignment, interferences from coeluting isomers/isobars are effectively filtered out to provide improved quantitative accuracy. From wild-type and Alzheimer's disease (AD) mouse brains, we successfully quantified 20 l-AAs and 5 d-AAs. The significant presence and differential trends of certain d-AAs compared to those of their l-counterparts provide valuable insights into the involvement of d-AAs in aging, AD progression, and neurodegeneration.

    View details for DOI 10.1021/acs.analchem.3c03847

    View details for PubMedID 38033201

    View details for PubMedCentralID PMC10872458

  • Quantification of Serum Metabolites in Early Colorectal Adenomas Using Isobaric Labeling Mass Spectrometry. Journal of proteome research Liu, Y., Zhang, H., Dove, W. F., Wang, Z., Zhu, Z., Pickhardt, P. J., Reichelderfer, M., Li, L. 2023; 22 (5): 1483-1491

    Abstract

    A major challenge in reducing the death rate of colorectal cancer is to screen patients using low-invasive testing. A blood test shows a high compliance rate with reduced invasiveness. In this work, a multiplex isobaric tag labeling strategy coupled with mass spectrometry is adopted to relatively quantify primary and secondary amine-containing metabolites in serum for the discovery of metabolite level changes of colorectal cancer. Serum samples from patients at different risk statuses and colorectal cancer growth statuses are studied. Metabolite identification is based on accurate mass matching and/or retention time of labeled metabolite standards. We quantify 40 metabolites across all the serum samples, including 18 metabolites validated with standards. We find significantly decreased levels of threonine and asparagine in the patients with growing adenomas or high-risk adenomas (p < 0.05). Glutamine levels decrease in patients with adenomas of unknown growth status or high-risk adenomas. In contrast, arginine levels are elevated in patients with low-risk adenoma. Receiver operating characteristic analysis shows high sensitivity and specificity of these metabolites for detecting growing adenomas. Based on these results, we conclude that a few metabolites identified here might contribute to distinguishing colorectal patients with growing adenomas from normal individuals and patients with unknown growth status of adenomas.

    View details for DOI 10.1021/acs.jproteome.3c00006

    View details for PubMedID 37014956

    View details for PubMedCentralID PMC10276621